SciTech Development Announces IRB Approval for Human Clinical Trials
SciTech Development Announces IRB Approval for Human Clinical TrialsLead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board (“IRB”) approval for its upcoming clinical trials for T-Cell Lymphomas. NEWS PROVIDED BY SciTech Development, LLC September 14, 2023 GROSSE POINTE FARMS, Mich., September 14, 2023 (Newswire.com) – SciTech Development (“SciTech” or the “Company”), a clinical-stage…